CLINICAL RESEARCH IN STEM CELL TRANSPLANTATION

正在进行的工作和拟议的研究中所描述的， 作为一个共同的主题，使用免疫疗法作为一种辅助手段， 晚期或高危原发性乳腺癌大剂量化疗 癌 三个可行性研究的描述，形成的基础上， 拟议的临床试验，其中两个是第二阶段，其中一个是 随机研究。 Bearman博士的同事进行了一项回顾性分析， 亚戈·涅托博士，已经导致了一个模型的发展，以预测病人 患有高风险原发性乳腺癌的患者， 自体移植 该模型将确定两个候选人， 拟进行临床试验。 该应用程序还描述了比尔曼博士如何 将培训年轻的研究人员进行以病人为中心的研究。 UCHSC骨头 骨髓移植计划有足够的患者进行这些研究， 积极进行实验室和临床研究，并由双方资助 同行评审和药物支持。 比尔曼博士会拿出50% 为这个五年计划而努力。

The ongoing work and the proposed studies described in this application have, as a common theme, the use of immunotherapy as an adjunct to high-dose chemotherapy for patients with advanced or high-risk primary breast cancer. Three feasibility studies are described which form the basis for the proposed clinical trials, two of which are phase II and one of which is a randomized study. A retrospective analysis performed by Dr. Bearman's fellow, Dr. Yago Nieto, has resulted in the development of a model to predict patients with high-risk primary breast cancer who are at high-risk of relapse after autologous transplant. That model will identify candidates for two of the proposed clinical trials. This application also describes how Dr. Bearman will trainee young investigators in patient-oriented research. The UCHSC Bone Marrow Transplant Program has sufficient patients to conduct these studies, actively conducts both laboratory and clinical research, and is funded by both peer-reviewed and pharmaceutical support. Dr. Bearman will devote 50 percent effort to this 5 year program.